University of Arkansas for Medical Sciences (UAMS) / Center for Addiction Services and Treatment (CAST)
Welcome,         Profile    Billing    Logout  
 4 Trials 
7 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Oliveto, Alison
NCT06233799: Trial of Naltrexone/Bupropion for the Treatment of Methamphetamine Use Disorder

Recruiting
3
360
US
extended-release naltrexone (XR-NTX), Vivitrol, extended release bupropion (BUP-XL) tablets (BUP-XL), Wellbutrin, iPLB, Placebo injections, oPLB, Placebo tablets
National Institute on Drug Abuse (NIDA)
Methamphetamine-dependence, Methamphetamine Abuse
10/26
04/27
CURB-2, NCT05262270: Extended-Release Naltrexone and Monthly Extended-Release Buprenorphine for Cocaine Use Disorder

Recruiting
2
426
US
Extended-Release Naltrexone, XR-NTX, Extended Release Buprenorphine, XR-BUP, Placebo (PLB) Injectable matched to XR-NTX, Injectable matching (to XR-NTX) placebo, Placebo (PLB) Injectable matched to XR-BUP, Injectable matching (to XR-BUP) placebo
University of Texas Southwestern Medical Center, National Institute on Drug Abuse (NIDA)
Cocaine Use Disorder
03/25
09/26
NCT04464980: Optimizing Retention, Duration and Discontinuation Strategies for Opioid Use Disorder Pharmacotherapy (RDD)

Recruiting
2
2190
US
SL-BUP, sublingual buprenorphine, Suboxone, XR-BUP, extended-release buprenorphine, CAM2038, Brixadi, XR-NTX, extended-release naltrexone, Vivitrol, MM, MMR, MMD
NYU Langone Health, New York State Psychiatric Institute, Columbia University, Harvard Medical School (HMS and HSDM), Mclean Hospital, National Institute on Drug Abuse (NIDA), The Emmes Company, LLC
Opioid Use Disorder (OUD)
07/26
12/26
NCT06055309: Behavioral Pharmacology of Cannabis in Older Adults

Not yet recruiting
1
5
US
Cannabis (up to three doses)
University of Arkansas
Health Services for the Aged
06/25
06/25
Gillespie, Michelle
NCT04464980: Optimizing Retention, Duration and Discontinuation Strategies for Opioid Use Disorder Pharmacotherapy (RDD)

Recruiting
2
2190
US
SL-BUP, sublingual buprenorphine, Suboxone, XR-BUP, extended-release buprenorphine, CAM2038, Brixadi, XR-NTX, extended-release naltrexone, Vivitrol, MM, MMR, MMD
NYU Langone Health, New York State Psychiatric Institute, Columbia University, Harvard Medical School (HMS and HSDM), Mclean Hospital, National Institute on Drug Abuse (NIDA), The Emmes Company, LLC
Opioid Use Disorder (OUD)
07/26
12/26
Locklear, Alyssah
CURB-2, NCT05262270: Extended-Release Naltrexone and Monthly Extended-Release Buprenorphine for Cocaine Use Disorder

Recruiting
2
426
US
Extended-Release Naltrexone, XR-NTX, Extended Release Buprenorphine, XR-BUP, Placebo (PLB) Injectable matched to XR-NTX, Injectable matching (to XR-NTX) placebo, Placebo (PLB) Injectable matched to XR-BUP, Injectable matching (to XR-BUP) placebo
University of Texas Southwestern Medical Center, National Institute on Drug Abuse (NIDA)
Cocaine Use Disorder
03/25
09/26
NCT04464980: Optimizing Retention, Duration and Discontinuation Strategies for Opioid Use Disorder Pharmacotherapy (RDD)

Recruiting
2
2190
US
SL-BUP, sublingual buprenorphine, Suboxone, XR-BUP, extended-release buprenorphine, CAM2038, Brixadi, XR-NTX, extended-release naltrexone, Vivitrol, MM, MMR, MMD
NYU Langone Health, New York State Psychiatric Institute, Columbia University, Harvard Medical School (HMS and HSDM), Mclean Hospital, National Institute on Drug Abuse (NIDA), The Emmes Company, LLC
Opioid Use Disorder (OUD)
07/26
12/26

Download Options